Ndc Drug And Chemical Company Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.50 M
- Revenue Growth 10.03%
- Profit Growth 78.54%
- Ebitda 29.01%
- Net Worth 14.29%
- Total Assets -5.86%
About Ndc Drug And Chemical Company
Ndc Drug And Chemical Company Private Limited (NDACCPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 14 June 2005 and has a history of 19 years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹4.50 M.
Ketan Shah, Jinesh Shah, and Nimesh Shah serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24200MH2005PTC153962
- Company No.
153962
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ndc Drug And Chemical Company?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nimesh Shah  | Director | 14-Jun-2005 | Current |
| Ketan Shah | Director | 14-Jun-2005 | Current |
| Jinesh Shah | Director | 14-Aug-2006 | Current |
Financial Performance of Ndc Drug And Chemical Company.
Ndc Drug And Chemical Company Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 10.03% increase. The company also saw a substantial improvement in profitability, with a 78.54% increase in profit. The company's net worth Soared by an impressive increase of 14.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ndc Drug And Chemical Company?
In 2021, Ndc Drug And Chemical Company had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹4.50 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of Travancore : 0.45 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Aug 2008 | State Bank Of Travancore | ₹4.50 M | Open |
How Many Employees Work at Ndc Drug And Chemical Company?
Unlock and access historical data on people associated with Ndc Drug And Chemical Company, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ndc Drug And Chemical Company, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ndc Drug And Chemical Company's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
